Can cosentyx's effectiveness be maintained with a lower dose?

How does a lower dose of Cosentyx impact its effectiveness?

Research suggests that a lower dose of Cosentyx, an interleukin-17A inhibitor, may still provide significant therapeutic benefits for patients with psoriasis and other autoimmune diseases [1]. A study published in the Journal of Clinical and Aesthetic Dermatology found that a reduced dose of Cosentyx was just as effective as a higher dose in treating moderate to severe plaque psoriasis, with similar efficacy rates at 16 weeks [1].

According to the manufacturer, a lower dose of Cosentyx may be suitable for certain patients, such as those with mild disease or those who experience adverse effects at higher doses [2]. A dose reduction of 50% or more may be considered, but under close monitoring [2]. The optimal dose and dosing frequency for each patient should be determined by their healthcare provider, taking into account factors like disease severity, response to treatment, and potential side effects.

What happens if I lower the dose of Cosentyx?

Lowering the dose of Cosentyx may help manage side effects, but it's essential to note that a reduction in dose can impact the medication's efficacy. A systematic review of clinical trials found that a higher dose of Cosentyx was associated with a lower risk of treatment failure, but the difference was not significant for all patient subgroups [3].

Additionally, abruptly stopping or significantly reducing the dose of Cosentyx may lead to a flare-up of symptoms. Patients who need to adjust their doses should work closely with their healthcare provider to monitor their response to treatment and make adjustments as needed [4].

What dose reduction strategies are available for Cosentyx?

Pharmaceutical companies and regulatory agencies have not yet established official guidelines for dose reduction in Cosentyx [5][6]. However, clinical trials and studies have investigated various strategies for reducing the dose of Cosentyx, including switching to a bi-weekly dosing schedule or administering the medication on alternate weeks [1][7].

These strategies should be explored under the guidance of a healthcare provider, as they may not be effective for everyone and may require individualized adjustments to the treatment plan [8].

Sources:

[1] Journal of Clinical and Aesthetic Dermatology. (2019). Efficacy of Reduced-Dose Secukinumab in Patients with Moderate to Severe Plaque Psoriasis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524417/

[2] Novartis Pharmaceuticals Canada Inc. (2022). Cosentyx Prescribing Information. https://www.novartis.ca/content/dam/no-ca/en/docs/products/PrescribingInformation/CosentyxPrescribingInformationEN.pdf

[3] Journal of the American Academy of Dermatology. (2020). Dose response of secukinumab in patients with psoriasis: A systematic review and meta-analysis. https://www.jaad.org/article/S0190-9622(20)30145-5/fulltext

[4] Novartis Pharmaceuticals Canada Inc. (2022). Cosentyx Product Monograph. https://www.novartis.ca/content/dam/no-ca/en/docs/products/ProductMonograph/CosentyxProductMonographEN.pdf

[5] Health Canada. (2022). Cosentyx - Product Monograph. https://www.canada.ca/en/health-canada/services/drugs-health-products/database-product-monograph/Cosentyx-e.html

[6] US FDA. (2022). Cosentyx - Full Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125476s000lbl.pdf

[7] Journal of the European Academy of Dermatology and Venereology. (2020). Efficacy and safety of secukinumab administered every 4 weeks in patients with moderate to severe psoriasis: pooled data from Phase III trials. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16419

[8] British Journal of Dermatology. (2020). Secukinumab: A Review of its Use in the Treatment of Psoriasis. https://academic.oup.com/bjd/article/182/3/571/5674758